New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia

NCT ID NCT07429461

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests SYNCAR-100, a type of cell therapy (CAR-T), in 16 adults with CD19-positive B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. Participants receive four weekly injections, then are followed for safety and tumor response for one year, with long-term monitoring up to 15 years. The main goal is to check safety and tolerability, with secondary goals looking at how well the therapy works against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYNCAR-100 (a CAR-T cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong: This is a very early, small study (16 people) focused on safety, not proof of effectiveness. The therapy may cause severe side effects or fail to control the disease long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

The first affiliated hospital of medical college of zhejiang university
RECRUITING

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.